Facts and controversies in the use of trastuzumab in the adjuvant setting.
about
Evidence-based health care policy in reimbursement decisions: lessons from a series of six equivocal case-studies.Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation.Therapeutic implications of the cancer stem cell hypothesis.Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts.Predicting response to radiotherapy: evolutions and revolutions.Trastuzumab and vinorelbine in early stages of HER2-positive breast cancer.
P2860
Facts and controversies in the use of trastuzumab in the adjuvant setting.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Facts and controversies in the use of trastuzumab in the adjuvant setting.
@en
Facts and controversies in the use of trastuzumab in the adjuvant setting.
@nl
type
label
Facts and controversies in the use of trastuzumab in the adjuvant setting.
@en
Facts and controversies in the use of trastuzumab in the adjuvant setting.
@nl
prefLabel
Facts and controversies in the use of trastuzumab in the adjuvant setting.
@en
Facts and controversies in the use of trastuzumab in the adjuvant setting.
@nl
P356
P1476
Facts and controversies in the use of trastuzumab in the adjuvant setting.
@en
P2093
Fatima Cardoso
Phuong Dinh
P2860
P304
P356
10.1038/NCPONC1219
P577
2008-09-09T00:00:00Z